linjc16/ctgov huggingface dataset:
Evaluation of Retreatment of Failed Revasculatized Teeth by Revascularization

Study Overview
=================
Brief Summary
-----------------
Study will include 30 participants with failed revascularized young permenant teeth that will be retreated by revascularization and evaluated for success through 2 years

Official Title
-----------------
Evaluation of Retreatment of Failed Revasculatized Teeth by Revascularization. Randomized Clinical Trial

Conditions
-----------------
Revascularization

Intervention / Treatment
-----------------
* Other: Revascularization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: central and lateral immature incisors child from 8- 10 years old healthy chidren failed revascularization Exclusion Criteria: medically compromised children mentally compromised children

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Revasularization<br>Revascularization of failed previously revascularized younge permenant inciors | Other: Revascularization<br>* Regain pulp vascularity for young permenant teeth<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Root completion | Continue root maturation by radiographic assessment according to cvek classification ( increase root length) | 2 years | 
| Increase dentine thickness | Increase dentine thickness as response to new formed pulp like tissues | 2 years | 
| Lesion healing | Resolvation of periapical lesion through new bone formation, intact lamina dura, abscence of periapical radiolucency | 2 years |
Preemptive Analgesia With Morphine Sulphate in Major Urological Surgery

Study Overview
=================
Brief Summary
-----------------
In this study safety and efficacy of oral morphine sulphate is evaluated in order to reduce opioids administration during major urological surgery

Detailed Description
-----------------
The administration of oral morphine sulfate could be useful to reduce the use of opioids in major urological surgery. This study aims to assess the safety and efficacy of two different oral morphine sulphate doses 0,2 mg/kg vs 0,4mg/kg in major urological surgery.

Official Title
-----------------
Influence of Premedication With Oral Morphine Sulphate on Analgesic Consumption in Patient Undergoing Major Urological Surgery. Comparison Between Two Different Doses

Conditions
-----------------
Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anaesthesiologists physical status classification I/ II, age between 18 - 75, BMI 18 -30 Exclusion Criteria: American Society of Anaesthesiologists physical status classification III/ IV, renal and hepatic insufficiency, postoperative nausea and vomiting after oral opioids administrations, neurological and psychiatric disorders.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 0,2 mg/kg oral morphine<br>Patients have been assigned to two groups of 20 individuals, they have been premedicated with oral morphine sulfate, 0,2 mg/kg group A, 0,4mg/kg group B.During surgery analgesic administration will be monitored | |
| 0,4 mg/ kg oral morphine<br>morphine and analgesic consumption throughout surgery will be monitored | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| morphine sulphate consumption |  | six months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| vital signs |  | six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
premedication, oral morphine, preemptive analgesia
National Gilles De La Tourette Study Group

Study Overview
=================
Brief Summary
-----------------
Tourette syndrome is rare. In France, about 3000 patients have a severe form of the disease. The aim of this study is to collect clinical characteristics in 200 patients with Tourette syndrome.

Conditions
-----------------
Tourette Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tourette syndrome Exclusion Criteria: severe cognitive disorders

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
KineSpring® System Patient Preference Study

Study Overview
=================
Brief Summary
-----------------
The primary objectives of the survey are to obtain patient preference information that can be useful during the benefit-risk assessment of the KineSpring System.

Detailed Description
-----------------
Well-established, quantitative research methods were employed to understand the relative importance of effectiveness, safety, and other characteristics of orthopedic surgical treatments and develop a benefit-risk model to inform regulatory decision making.

Official Title
-----------------
KineSpring® System Patient Preference Study

Conditions
-----------------
Osteoarthritis of the Knee

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females aged 25 - 80 years Diagnosed with osteoarthritis in the knee Experience pain in the knee of greater than or equal to a 4 on a 0 - 10 scale, where 0 means not at all painful and 10 means extremely painful Experience knee pain at least once a week Previously failed non-surgical treatments for knee OA pain Pass a security screen Exclusion Criteria: Do not suffer or has not been diagnosed with knee osteoarthritis Has had knee surgical intervention involving an implant or a prosthesis (i.e. total knee replacement, unicompartmental knee arthroplasty, high tibial osteotomy)

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Survey|Internet panelists, who self-reported that they or another adult in their household has osteoarthritis, were sent an email invitation to the survey site.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient preferences for knee osteoarthritis surgical procedures | Patient preference for knee osteoarthritis surgeries | At time of survey |
COVID-19 in Patients With Chronic Liver Diseases

Study Overview
=================
Brief Summary
-----------------
This study seeks to determine how COVID-19 affects the clinical outcome of patients with chronic liver disease, and whether the clinical course of COVID-19 is influenced by underlying chronic liver disease.

Official Title
-----------------
COVID-19 in Patients With Chronic Liver Diseases

Conditions
-----------------
COVID-19, Chronic Liver Disease

Intervention / Treatment
-----------------
* Other: Prospective Chart Review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of COVID-19 Personal history of either Chronic hepatitis C Chronic hepatitis B Alcoholic liver disease Non alcoholic liver disease Autoimmune hepatitis, Primary biliary cholangitis, Primary sclerosing cholangitis Cryptogenic cirrhosis Hepatocellular carcinoma Exclusion Criteria: Non-COVID-19 patient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic Liver Disease Group<br>COVID-19 patients with Chronic Liver Disease. | Other: Prospective Chart Review<br>* Collected data will include demographic features, clinical characteristics, clinical outcome, medication use, COVID-19-related complications in patients with chronic liver disease.<br>|
| Control Group<br>COVID-19 patients without Chronic Liver Disease. | Other: Prospective Chart Review<br>* Collected data will include demographic features, clinical characteristics, clinical outcome, medication use, COVID-19-related complications in patients with chronic liver disease.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality | Death due to any cause | 30 days | 
| All-cause mortality | Death due to any cause | 1 year | 
| Liver-related mortality | Death due to liver-related cause | 28 days | 
| Liver-related mortality | Death due to liver-related cause | 1 year | 
| Overall survival | Patients will be assessed for this outcome for up to 1 year | Up to 1 year | 
| Number of patients with hepatic decompensation | Onset of hepatic decompensation due to COVID-19 disease; patients will be assessed for this outcome for up to 1 year | Up to 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients requiring hospitalization | Patients will be assessed for this outcome for up to 1 year. | Up to 1 year | 
| Duration of hospitalization | Patients will be assessed for this outcome for up to 1 year. | Up to 1 year | 
| Length of intensive care unit (ICU) stay | Patients will be assessed for this outcome for up to 1 year. | Up to 1 year | 
| Number of participants requiring mechanical ventilation | Patients will be assessed for this outcome for up to 1 year. | Up to 1 year |
Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer

Study Overview
=================
Brief Summary
-----------------
This research study is evaluating the use of Cardiac Magnetic Resonance Imaging (CMR) as a method of detecting early signs of damage to the heart that can be associated with anthracycline-based chemotherapy for the treatment of breast cancer.

Detailed Description
-----------------
One of the side effects observed in breast cancer patients receiving anthracycline-based treatment is heart complications in which the heart muscle is weakened and no longer able to pump sufficient amounts of blood throughout the body. This complication can lead to the following symptoms: shortness of breath on exertion, swollen ankles and feet, lack of energy and a reduced capacity to carry out day-to-day activities. This research study is focused on identifying the early signs of such heart complications using CMR, which may allow preventative treatment options to be made available in future.

Official Title
-----------------
Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Other: Cardiac Magnetic Resonance Imaging (CMR)
* Other: Echocardiogram (ECHO)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Have histologic diagnosis of breast carcinoma Scheduled to receive standard clinical therapy designed by their treating oncologist Patients should receive anthracycline as part of the recommended treatment Able to give informed consent. Exclusion Criteria: Contraindication to contrast CMR including eGFR <30 mls/min/1.73m2 Uncontrolled serious concurrent illness Pregnancy or breast feeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CMR/ECHO<br>Prior to starting chemotherapy treatment, the participant will undergo the following procedures: Cardiac Magnetic Resonance Imaging (CMR) Echocardiogram (ECHO) in patients with no clinically indicated scans Each imaging procedure will be repeated at predetermined times during the protocol Simple blood collection for plasma biomarker analysis | Other: Cardiac Magnetic Resonance Imaging (CMR)<br>* Subjects will be recruited for observational cardiac magnetic resonance imaging.<br>* Other names: MRI;Other: Echocardiogram (ECHO)<br>* Subjects will undergo a research echocardiogram if a clinical echocardiogram has not already been ordered.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiotoxicity | Cardiotoxicity as measured by changes in left ventricular ejection fraction within one-year of completion of treatment | 1 year after completion of treatment |
Food Allergy Registry at a Single Site

Study Overview
=================
Brief Summary
-----------------
This is a registry of participants who are interested in being screened for clinical trials at a single site.

Detailed Description
-----------------
This registry will be maintained on a secure database and will include name, gender, age, disease, medical information, other information (via questionnaires), and date of consent. It will be overseen by our regulatory manager at our site and will not be shared with others outside of our site-specific trained individuals.

Official Title
-----------------
Food Allergy Registry at a Single Site

Conditions
-----------------
Allergy and Asthma

Intervention / Treatment
-----------------
* Other: There is no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any interested party from 0-100 yrs of age to enter their information in registry Exclusion Criteria: Any individual who does not consent

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: There is no intervention|There is no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Registry to provide a list of interested individuals in clinical trials at a single site | The clinical trials could be either allergy or asthma studies | 4 years |
Senescent Immunity in Elders and Vaccine Responses (SILVER)

Study Overview
=================
Brief Summary
-----------------
To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.

Official Title
-----------------
Single Cell Molecular Analysis of Influenza Vaccine Induced T Cell Responses in Adults 65 Years of Age or Older

Conditions
-----------------
Flu Vaccine

Intervention / Treatment
-----------------
* Biological: Fluzone-High Dose Quadrivalent
* Biological: Fluad
* Biological: Flublock


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 65 years and over Independent Living (including Assisted Living) Exclusion Criteria: Unable to understand the consent or the study. Allergic to any vaccine components, excluding eggs. History of Guillain-Barre. Residing in a long -term care facility such as a nursing home.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 125 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Fluzone-High Dose<br>FDA approved high dose inactivated influenza vaccine (HD-Fluzone) | Biological: Fluzone-High Dose Quadrivalent<br>* Seasonal influenza vaccination with FDA approved vaccines for this age group.<br>* Other names: High-dose flu vaccine;|
| Active Comparator: Fluad<br>Adjuvanted (MF59) inactivated influenza vaccine (Fluad) | Biological: Fluad<br>* Adjuvanted (MF59) inactivated influenza vaccine<br>* Other names: standard-dose, inactivated influenza (flu) vaccine;|
| Active Comparator: Recombinant Hemagglutinin vaccine (Flublok)<br>Recombinant hemagglutinin vaccine | Biological: Flublock<br>* Recombinant hemagglutinin vaccine<br>* Other names: Recombinant Hemagglutinin vaccine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemagglutinin Antigen Inhibition Assay Titers at Baseline | 2 fold dilution series of serum, and measurement of titer which inhibits hemagglutination. Titers were measured for each of 4 antigens in the vaccine (A/Brisbane/2018 (H1N1), A/Kansas/2017 (H3N2), B/Colorado/2017 (Vic), B/Phuket/2013 (Yam)) | Baseline Baseline | 
| Hemagglutinin Antigen Inhibition Assay Titers at Day 28 | 2 fold dilution series of serum, and measurement of titer which inhibits hemagglutination. Titers were measured for each of 4 antigens in the vaccine (A/Brisbane/2018 (H1N1), A/Kansas/2017 (H3N2), B/Colorado/2017 (Vic), B/Phuket/2013 (Yam)) | Day 28 Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adult 65 and older
Racial Differences: Nitric Oxide(NO) and Endothelin-1(ET-1) in Preeclampsia (PreE)

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to examine the activation of markers of endothelial and cardiovascular dysfunctions, from women with high-risk pregnancies. Information from this study will hopefully provide enough information to determine a link between race, the advent of high risk pregnancies and cardiovascular markers. With this information it might be possible to intervene with approved pharmacological treatments.

Official Title
-----------------
Elucidating the Role of Nitric Oxide and Endothelin-1 Activation in Endothelial Cells Co-cultured With Placental Explants From African-american and Caucasian High Risk Pregnancies

Conditions
-----------------
Preeclampsia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: African-american or Caucasian Pregnant Between ages of 18 - 40 years of age Exclusion Criteria: Presence of a disease or condition which is not preeclampsia Drug or alcohol abuse during pregnancy Obesity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A, 1, I<br>Caucasian women without preeclampsia or PIH, delivering their first child | |
| A, 1, II<br>Caucasian women with preeclampsia or PIH, delivering their first child | |
| A, 2, I<br>African-american women without preeclampsia or PIH, delivering their first child | |
| A, 2, II<br>African-American women with preeclampsia or PIH, delivering their first child | |
| B, 1, I<br>Caucasian women without preeclampsia or PIH, delivering at least their second child | |
| B, 1, II<br>Caucasian women with preeclampsia or PIH, delivering at least their second child | |
| B, 2, I<br>African-american women without preeclampsia or PIH, delivering at least their second child | |
| B, 2, II<br>African-american women with preeclampsia or PIH, delivering at least their second child | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nitric oxide and Endothelin-1 levels |  | 48 hours after tissue collection | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nitric oxide isoforms and Endothelin-1 receptor activation based on primary outcome |  | within 6 months from tissue collection |
Ovarian Cancer and Immune Response to Flu Vaccine

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine what the immune response is of ovarian cancer patients in remission, when they are given the flu vaccine. After receiving the flu vaccine, patients will have blood drawn 5 times in 12 months to study antibody response to the flu vaccine.

Official Title
-----------------
Study of the Immunogenicity of Killed Influenza Vaccine in Patients With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Remission

Conditions
-----------------
Ovarian Cancer

Intervention / Treatment
-----------------
* Biological: The current season's trivalent killed influenza vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All subjects must have a histologic diagnosis of epithelial ovarian cancer or primary peritoneal carcinoma. Time from completion of chemotherapy will be no more than 6 months. If no clinical evidence of disease is present after diagnosis with Stage III or IV disease and completion of primary surgery and chemotherapy, or, if no clinical evidence of disease is present after completion of chemotherapy for a disease recurrence diagnosed after a progression-free interval of at least 2 years, for patients of any initial stage. Exclusion Criteria: Prior malignancy (except basal cell or squamous cell skin cancer) within the past five years. Presence of active CNS disease. Active bacterial, viral or fungal infections. Chemotherapy, biologic therapy, or radiation therapy < 4 weeks prior to study entry. History of active autoimmunity or immunosuppression. Use of immunosuppressive drugs within 4 weeks prior to study entry. Patients may receive chemotherapy or other immunosuppressive medications at the discretion of their physician during the subsequent year after influenza vaccination without exclusion from the study. Patients with tumors of low malignant potential (borderline tumors) will not be eligible. Prior influenza vaccination with the current vaccine. History of serious sensitivity to eggs, or previous influenza vaccine. Pregnant of breastfeeding subjects.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: The current season's trivalent killed influenza vaccine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Advanced Ovarian and Primary Peritoneal Cancer in Remission